Ranibizumab Prefilled Syringe Approved for Diabetic Retinopathy

Article

Diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 years in the US.

The FDA has approved ranibizumab injection 0.3 mg prefilled syringe (Lucentis) as a new method to administer the therapy to all forms of diabetic retinopathy (DR) in people with or without diabetic macular edema (DME).

The approval of the injection therapy from Genentech came April 2017, when it became the first and only FDA-approved therapy for all forms of DR in people with or without DME. The prefilled syringe options are now approved by the FDA for all use in all of Lucentis’ indications.

With the approval, the 0.3 mg prefilled syringe becomes the first syringe with anti-vascular endothelial growth factor (VEGF) agent approved by the FDA for use to treat DR and DME.

For more information, please visit MDMag.com.

Related Videos
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
pain management palliative care/Image Credits: © Aleksej - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.